# Korean Post-marketing Surveillance Vyndamax® Capsules for the Treatment of Transthyretin Amyloid Cardiomyopathy

> **NCT04801329** · — · ACTIVE_NOT_RECRUITING · sponsor: **Pfizer** · enrollment: 110 (actual)

## Conditions studied

- ATTR-CM (Transthyretin Amyloid Cardiomyopathy)

## Interventions

- **DRUG:** Vyndamax (tafamidis 61mg)

## Key facts

- **NCT ID:** NCT04801329
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-06-29
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04801329

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04801329, "Korean Post-marketing Surveillance Vyndamax® Capsules for the Treatment of Transthyretin Amyloid Cardiomyopathy". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04801329. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*